Can a large-scale genome-wide association study (GWAS) meta-analysis identify genomic risk loci and likely involved genes for female genital tract (FGT) polyps, provide insights into the biological mechanism underlying their …
Endometrial cysts of the ovary (EMC) may develop into endometriosis (EM)‑associated ovarian cancer over time (EAOC), but the pathogenesis of this disease has not been determined. In the present study, …
Endometriosis is common and poses significant morbidity of lasting impact to young, pre-menopausal women, while ovarian cancer is a lethal gynecologic condition. Both conditions need better treatment. The human omentum …
Female health and the microbiota of the reproductive tract are closely associated. The research scope on reproductive tract microbiota extends from the vaginal to the upper reproductive tract and from …
Ovarian squamous cell carcinoma [SCC] is a rare and aggressive malignancy that can mimic benign gynecological disorders, often leading to diagnostic delays and suboptimal management. Ureteral obstruction and subsequent hydroureteronephrosis …
What is the risk of endometrial cancer after long-term follow-up in women treated with ART between 1983 and 2001 compared with women in the general population and subfertile women who …
Endometriosis may become malignant, and its diagnosis is challenging, especially in rare extra-ovarian sites like the rectum. Here, we describe the case of a 42-year-old woman who presented with intermittent …
A chronic illness known as endometriosis impacts women who are of reproductive maturity. It may be a factor in fertility problems, breast or ovarian cancer, asthma, cardiovascular illness, or pelvic …
Endometriosis (EMs) is a chronic inflammatory disease characterized by the presence of endometrial tissue in the non-uterine cavity, resulting in dysmenorrhea, pelvic pain, and infertility. Epidemiologic data have suggested the …
Relugolix is an oral gonadotropin-releasing hormone receptor antagonist that suppresses sex steroid hormones and is approved as monotherapy for prostate cancer and as a fixed-dose combination with estradiol/norethindrone for the …